Emergent BioSolutions (STU:ER4) EV-to-EBIT : -2.35 (As of May. 17, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Emergent BioSolutions's Enterprise Value is €1,013 Mil. Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-432 Mil. Therefore, Emergent BioSolutions's EV-to-EBIT for today is -2.35.

The historical rank and industry rank for Emergent BioSolutions's EV-to-EBIT or its related term are showing as below:

STU:ER4' s EV-to-EBIT Range Over the Past 10 Years
Min: -35512.2 Med: 13.84 Max: 80.28
Current: -2.36

During the past 13 years, the highest EV-to-EBIT of Emergent BioSolutions was 80.28. The lowest was -35512.20. And the median was 13.84.

STU:ER4's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.59 vs STU:ER4: -2.36

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Emergent BioSolutions's Enterprise Value for the quarter that ended in Mar. 2024 was €885 Mil. Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-432 Mil. Emergent BioSolutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -48.81%.

Emergent BioSolutions EV-to-EBIT Historical Data

The historical data trend for Emergent BioSolutions's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions EV-to-EBIT Chart

Emergent BioSolutions Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

29.64

11.31

7.39

-7.46

-1.36

Emergent BioSolutions Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-4.59	-2.53	-1.44	-1.36	-2.07

Competitive Comparison of Emergent BioSolutions's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's EV-to-EBIT falls into.

Emergent BioSolutions EV-to-EBIT Calculation

Emergent BioSolutions's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1013.452	/	-431.816
	=	-2.35

Emergent BioSolutions's current Enterprise Value is €1,013 Mil.
Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-432 Mil.

Emergent BioSolutions (STU:ER4) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Emergent BioSolutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-431.816	/	884.7672
	=	-48.81 %

Emergent BioSolutions's Enterprise Value for the quarter that ended in Mar. 2024 was €885 Mil.
Emergent BioSolutions's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-432 Mil.

Emergent BioSolutions EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Emergent BioSolutions (STU:ER4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

EBS:USA ER4:Germany

Address

400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879

Website

https://www.emergentbiosolutions.com

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines